Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia

Langenbecks Arch Surg. 2017 Sep;402(6):873-883. doi: 10.1007/s00423-017-1603-8. Epub 2017 Jul 21.

Abstract

Purpose: Indications for total pancreatectomy (TP) have increased, including for diffuse main duct intrapapillary mucinous neoplasms of the pancreas and malignancy; therefore, the need persists for surgeons to develop appropriate endocrine post-operative management strategies. The brittle diabetes after TP differs from type 1/2 diabetes in that patients have absolute deficiency of insulin and functional glucagon. This makes glucose management challenging, complicates recovery, and predisposes to hospital readmissions. This article aims to define the disease, describe the cause for its occurrence, review the anatomy of the endocrine pancreas, and explain how this condition differs from diabetes mellitus in the setting of post-operative management. The morbidity and mortality of post-TP endocrine insufficiency and practical treatment strategies are systematically reviewed from the literature. Finally, an evidence-based treatment algorithm is created for the practicing pancreatic surgeon and their care team of endocrinologists to aid in managing these complex patients.

Methods: A PubMed, Science Citation Index/Social sciences Citation Index, and Cochrane Evidence-Based Medicine database search was undertaken along with extensive backward search of the references of published articles to identify studies evaluating endocrine morbidity and treatment after TP and to establish an evidence-based treatment strategy.

Results: Indications for TP and the etiology of pancreatogenic diabetes are reviewed. After TP, ~80% patients develop hypoglycemic episodes and 40% experience severe hypoglycemia, resulting in 0-8% mortality and 25-45% morbidity. Referral to a nutritionist and endocrinologist for patient education before surgery followed by surgical reevaluation to determine if the patient has the appropriate understanding, support, and resources preoperatively has significantly reduced morbidity and mortality. The use of modern recombinant long-acting insulin analogues, continuous subcutaneous insulin infusion, and glucagon rescue therapy has greatly improved management in the modern era and constitute the current standard of care. A simple immediate post-operative algorithm was constructed.

Conclusion: Successful perioperative surgical management of total pancreatectomy and resulting pancreatogenic diabetes is critical to achieve acceptable post-operative outcomes, and we review the pertinent literature and provide a simple, evidence-based algorithm for immediate post-resection glycemic control.

Keywords: Endocrine insufficiency; IPMN; Management; Pancreatogenic diabetes; Total pancreatectomy.

Publication types

  • Review

MeSH terms

  • Aged
  • Blood Glucose / analysis
  • Diabetes Mellitus, Type 1 / etiology*
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetes Mellitus, Type 1 / therapy
  • Disease Management
  • Evidence-Based Medicine
  • Female
  • Humans
  • Hypoglycemia / physiopathology
  • Hypoglycemia / therapy
  • Insulin / administration & dosage*
  • Male
  • Middle Aged
  • Pancreatectomy / adverse effects*
  • Pancreatectomy / methods*
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery*
  • Perioperative Care / methods*
  • Postoperative Complications / physiopathology
  • Postoperative Complications / therapy
  • Quality of Life
  • Risk Assessment
  • Treatment Outcome

Substances

  • Blood Glucose
  • Insulin